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Kosuke Kosai1*, Hiromichi Suzuki2, Kiyoko Tamai3, Yuya Okada1, Norihiko Akamatsu1, 
Atsuo Ueda4, Shigeyuki Notake4, Yuji Yaguchi3 & Katsunori Yanagihara1,5
We investigated the efficiency of the Verigene Enteric Pathogens Nucleic Acid Test (Verigene EP test), 
which is an automated microarray-based assay system that enables rapid and simultaneous genetic 
detection of gastrointestinal pathogens and toxins, including those in the Campylobacter Group, 
Salmonella species, Shigella species, the Vibrio Group, Yersinia enterocolitica, Shiga toxin 1 and 2, 
norovirus GI/GII, and rotavirus A. Three clinical laboratories evaluated the Verigene EP test, using 268 
stool samples for bacterial and toxin genes and 167 samples for viral genes. Culture-based reference 
methods were used for the detection of bacteria and toxins, while a different molecular assay was 
used for viral detection. The overall concordance rate between the Verigene EP test and the reference 
methods for the 1940 assays was 99.0%. The overall sensitivity and specificity of the Verigene EP test 
were 97.0% and 99.3%, respectively. Of the 19 samples with discordant results, 13 samples were false 
positives and six were false negatives. The Verigene EP test simultaneously detected two targets in 11 
samples; overall, the test demonstrated high efficiency in detecting crucial diarrheagenic pathogens, 
indicating its suitability for clinical practice.
Acute infectious diarrhea is a major cause of outpatient visits and  hospitalization1. Since most diarrheal illnesses 
are self-limited, microbiological testing is not necessary for all patients. However, rapid etiological identification 
is required for those with serious symptoms and conditions such as systemic illness, fever, and bloody  stool2, to 
enable effective antimicrobial treatment against specific pathogens. Furthermore, because some patients with 
infectious diarrhea should be isolated to prevent pathogen transmission in hospitals, more prompt and accurate 
methods are needed to detect crucial gastrointestinal pathogens.
The Verigene Enteric Pathogens Nucleic Acid Test (Verigene EP test) (Luminex Corporation) is an automated 
system based on microarray technology that enables simultaneous detection of enteric pathogens faster (3 h or 
less, including handling time) than conventional stool  culture3. Since only a few previous studies have investi-
gated the utility of this  test3,4, and epidemiological differences affect the performance of diagnostic  methods5, 
we conducted a multicenter evaluation in Japan to assess the ability of the Verigene EP test to detect crucial 
enteric pathogens.
Materials and methods
Study design. We examined clinical stool samples submitted to laboratories at the Nagasaki University 
Hospital, Tsukuba Medical Center Hospital, and Miroku Medical Laboratory between October 2016 and March 
2018. The assay for this study was performed soon after routine testing or using samples stored at − 80 °C.
All research was performed in accordance with the Declaration of Helsinki and the Ethical Guidelines for 
Medical and Health Research Involving Human Subjects, which was issued by the Japanese Ministry of Educa-
tion, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare. Informed consent 
was obtained using the opt-out method provided on the website. The Institutional Review Board of Nagasaki 
University Hospital approved this study (approval number 16062725/18070902).
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Verigene EP test. The Verigene EP test, which has been approved for use in clinical settings by the Food 
and Drug Administration (FDA) in the United States and by the Pharmaceuticals and Medical Devices Agency 
(PMDA) in Japan, was used according to the manufacturer’s instructions. The test requires a processor, a reader, 
and single-use consumables. To prepare the fecal suspension for the assay, a swab dipped into stool was mixed 
with Stool Prep Buffer for 15–20 s using a vortex mixer. Extraction Tray, Tip Holder Assembly, Amplification 
Tray, and Test Cartridge were loaded into the processor. After centrifugation, 200  µL of the suspension was 
loaded into the Sample Loading Well of the Extraction Tray. Nucleic acid extraction, amplification, and nanopar-
ticle-based microarray hybridization were automatically performed on the processor, and the data were analyzed 
by the reader. The Verigene EP test is aimed at the genetic detection of Campylobacter Group (C. jejuni, coli, and 
lari), Salmonella species, Shigella species (S. boydii, sonnei, flexneri, and dysenteriae), Vibrio Group (V. cholerae 
and parahaemolyticus), Yersinia enterocolitica, Shiga toxin (Stx) 1 and 2, norovirus GI/GII, and rotavirus  A3,4,6. 
The test does not target protozoa.
Culture methods. Culture-based methods for the detection of bacteria and toxins were performed based on 
the guidelines for the diagnostic testing of enteric infections, textbooks, and the manufacturer’s  instructions7–9. 
The media used and the identification methods are listed in Supplemental Table 1. We did not use enrichment 
broth for the cultures. In addition to cultures, reversed passive latex agglutination, and enzyme immunoassay 
were used for detecting Shiga toxins.
xTAG Gastrointestinal Pathogen Panel. The assay was performed with the FDA-approved xTAG Gas-
trointestinal Pathogen Panel (GPP) (Luminex Corporation), according to the manufacturer’s instructions. xTAG 
GPP requires prior nucleic acid extraction, multiplex amplification, and bead hybridization; the test can detect 
the genes of 15 gastrointestinal pathogens and toxins (nine bacteria and toxins, three viruses, and three pro-
tozoa), with several recent studies validating its  performance3,10–12. An inoculating loop dipped into stool or 
100 μL of watery diarrheal stool was added to a Bertin SK38 Soil Grinding Lysis Bead Tube with NucliSENS 
easyMAG Lysis Buffer (bioMérieux) or ASL Lysis Buffer (Qiagen). Ten μL of xTAG MS2 (internal control) was 
added, except in the negative control tube. The tube was mixed for 5 min using a vortex mixer, settled at room 
temperature for 10–15 min, and centrifuged at 14,000 rpm for 2 min. 200 μL of the supernatant was removed 
from the middle of the layer and used for nucleic acid extraction, using the QIAamp MinElute Virus Spin Kit 
(Qiagen) according to the manufacturer’s instructions. Ten μL of the nucleic acid sample was mixed with 15 μL 
of prepared multiplex PCR master mix, and the PCR reactions were performed under the following conditions: 
20 min at 53 °C, 15 min at 95 °C, 38 cycles consisting of 30 s at 95 °C, 30 s at 58 °C, 30 s at 72 °C, and 2 min at 
72 °C for the final extension. Five μL of the PCR product was mixed with 20 μL xTAG GPP Bead Mix and 75 
μL xTAG SAPE (Streptavidin, R-Phycoerythrin Conjugate) diluted 75 times with xTAG Reporter Buffer. Bead 
hybridization was performed under the following conditions: 3 min at 60 °C and 45 min at 45 °C. Data were 
analyzed using the xTAG Data Analysis Software LSM version 2.00 after data acquisition using the MAGPIX 
 System13.
Multiplex real-time PCR. Multiplex real-time PCR assay for viral detection was performed by BML, INC. 
as  follows14,15. Briefly, a 10% (wt/vol) stool suspension was prepared with distilled sterile water and centrifuged 
at 3000×g for 20 min. Nucleic acid was extracted from 140 μL of the stool suspension using NucleoMag (Takara 
Bio Inc.) or QIAamp Virus RNA Mini Kit (Qiagen) according to the manufacturer’s instructions. The extracted 
nucleic acid was eluted with 60 μL of diethyl pyrocarbonate-treated water and stored at – 80 °C until use. After 
reverse transcription using PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio Inc.) according to the manu-
facturer’s instructions, multiplex PCR was performed using the QuantiTect Multiplex PCR kit (Qiagen) on a 
LightCycler 480 System (Roche Diagnostics). Amplification was carried out in 50 μL reaction mixture contain-
ing 5 μL nucleic acid sample. The reaction steps were as follows: 15 min at 95 °C and 40 cycles consisting of 1 min 
at 94 °C and 90 s at 60 °C. Primers and probes for the detection of norovirus GI/GII and rotavirus A genes have 
been described  elsewhere14,15.
Reference methods and discrepant analysis. Culture-based methods were used as reference methods 
for the detection of bacteria and toxins. The xTAG GPP was used as a reference method for viral detection. For 
the detection of bacteria and toxins, a discrepant analysis was performed by re-examination using the Verigene 
EP test for the samples with false-negative results or by the assay using the xTAG GPP for the samples with false-
positive results. Discrepant analysis for each virus was performed using multiplex real-time PCR.
Efficiency of the Verigene EP test. We calculated the sensitivity and specificity of the Verigene EP test 
in detecting targets, based on results from the reference methods, and determined the 95% confidence intervals 
using the software R version 3.5.116.
Assessment using characterized stool samples. To evaluate the ability of the Verigene EP test to 
detect pathogens present only in a few clinical samples, we assessed characterized stool samples. A stool sample 
obtained from BizCom Japan, Inc., which was confirmed to be negative for the target pathogens by the Verigene 
EP test and culture, was used for this analysis. To prepare 200 μL of characterized samples, 8 μL of bacterial sus-
pension, 160 μL of the Stool Prep Buffer, and 32 μL of stool were mixed. The target bacterial concentrations in 
the characterized samples were twice or 20 times the limit of detection (LoD) of the Verigene EP test. The LoD 
information was provided by the Luminex Corporation, and the LoD used in this study was 1.11 × 105 colony-
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forming units (CFU)/mL, which was the highest LoD among Shigella species. The concentration of the bacterial 
suspension was adjusted using the McFarland turbidity standard. Serial dilutions of bacterial suspensions were 
plated onto agar medium, and the actual concentration was calculated by counting the number of bacterial 
colonies.
Results
Detection ability of Verigene EP test for clinical stool samples. We examined 268 clinical stool 
samples for bacteria and toxins (266 samples for Stx 1 and 2) and 167 samples for viruses. Of the 268 samples 
tested for bacteria and toxins and the 167 samples tested for viruses, 256 and 160 samples respectively (95.5% 
and 95.8%) had fully concordant results between the Verigene EP test and the reference methods. Table 1 depicts 
the detection ability of the Verigene EP test for clinical samples as compared to the reference methods. The over-
all sensitivity and specificity of the test were 97.0% (195/201) and 99.3% (1726/1739), respectively. The sensitivity 
ranged from 87.5% for rotavirus (7/8) to 100.0% for the Campylobacter Group (47/47), Shigella species (2/2), Y. 
enterocolitica (16/16), and Stx 1 and 2 (25/25). Similarly, the specificity ranged from 97.7% for norovirus GI/GII 
(126/129) to 100.0% for Shigella species (266/266) and the Vibrio Group (259/259).
Of the 19 samples with discordant results, 13 and six were false positives and false negatives, respectively. 
Seven of the 13 false-positive samples were positive, and one out of the six false-negative samples was negative 
in the discrepant analysis (Table 1).
The Verigene EP test simultaneously detected two targets in 11 samples (Table 2). Of these 11 samples, five 
samples showed fully concordant results between the Verigene EP test and the reference methods, whereas six 
samples exhibited partial concordance between the two (Table 2).
Table 1.  Efficiency of the Verigene Enteric Pathogens Nucleic Acid Test to detect pathogens and toxin 
genes for clinical stool samples. Data were compared to reference methods and expressed as numbers or 
percentages (95% confidence interval). TP true positive, TN true negative, FP false positive, FN false negative. 
a Campylobacter jejuni, coli, and lari. b Shigella boydii, sonnei, flexneri, and dysenteriae. c Vibrio cholerae and 
parahaemolyticus. d All samples were positive in the discrepant analysis. e The sample was negative in the 
discrepant analysis. f All samples were positive in re-examination using the Verigene EP test. g One sample was 
positive and two samples were negative in the discrepant analysis. h One sample was positive and the other was 
negative in the discrepant analysis.
Pathogen and toxin gene TP TN FP FN Sensitivity (%) Specificity (%)
Bacterium
Campylobacter  Groupa 47 219 2d 0 100.0 (92.5–100.0) 99.1 (96.8–99.9)
Salmonella species 53 211 1e 3f 94.6 (85.1–98.9) 99.5 (97.4–100.0)
Shigella  speciesb 2 266 0 0 100.0 (15.8–100.0) 100.0 (98.6–100.0)
Vibrio Groupc 8 259 0 1f 88.9 (51.8–99.7) 100.0 (98.6–100.0)
Yersinia enterocolitica 16 249 3g 0 100.0 (79.4–100.0) 98.8 (96.6–99.8)
Shiga toxin 1 and 2 25 239 2h 0 100.0 (86.3–100.0) 99.2 (97.0–99.9)
Virus
Norovirus GI/GII 37 126 3d 1e 97.4 (86.2–99.9) 97.7 (93.4–99.5)
Rotavirus A 7 157 2h 1d 87.5 (47.3–99.7) 98.7 (95.5–99.8)
Overall 195 1726 13 6 97.0 (93.6–98.9) 99.3 (98.7–99.6)
Table 2.  Detection of multiple targets by the Verigene Enteric Pathogens Nucleic Acid Test and comparative 
analysis.
Detection by Verigene EP test Detection by reference methods Results of discrepant analysis
Campylobacter Group and Salmonella species Campylobacter Group and Salmonella species –
Campylobacter Group and Vibrio Group Campylobacter Group and Vibrio Group –
Campylobacter Group and rotavirus A Campylobacter Group only Negative for rotavirus A
Salmonella species and Y. enterocolitica Salmonella species only Positive for Y. enterocolitica
Salmonella species and norovirus GI/GII Salmonella species and norovirus GI/GII –
Vibrio Group and Y. enterocolitica Vibrio Group only Negative for Y. enterocolitica
Vibrio Group and Shiga toxin Vibrio Group only Positive for Shiga toxin
Y. enterocolitica and Shiga toxin Y. enterocolitica only Negative for Shiga toxin
Shiga toxin and norovirus Shiga toxin and norovirus –
Y. enterocolitica and norovirus GI/GII Y. enterocolitica and norovirus GI/GII –
Y. enterocolitica and norovirus GI/GII Norovirus GI/GII only Negative for Y. enterocolitica
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Detection ability of Verigene EP test for characterized stool samples. Since the clinical stool 
samples included only two samples positive for Shigella species, we assessed the ability of Verigene EP test to 
detect the pathogen using characterized stool samples. We used 26 Shigella sonnei strains, which were previously 
isolated and stored in our institutions, and 13 strains were used in the preparation of characterized stool samples 
with concentrations targeting twice or 20 times the LoD of the Verigene EP test. The actual bacterial concen-
trations of these samples were 0.1–2.6 × 105 CFU/mL or 5.0 × 105–1.0 × 106 CFU/mL. Of the 26 characterized 
samples examined, the Verigene EP test correctly detected S. sonnei in 25 samples, except for one sample with a 
bacterial concentration of 2.6 × 105 CFU/mL.
Discussion
Our study results demonstrated that the Verigene EP test accurately detected the genes of enteric pathogens and 
toxins in clinical samples with high sensitivity and specificity, which is consistent with previous  reports3,4. Due 
to the ability of the test to detect multiple targets in a single assay, the Verigene EP test can avoid overlooking 
of any crucial gastrointestinal pathogens. Furthermore, the Verigene EP test enables rapid diagnosis with less 
work or training for laboratory  technicians12; on the other hand, conventional bacterial cultures are labor- and 
time-intensive. Additionally, unnecessary use of antimicrobial drugs and the duration of patient isolation may 
be reduced because of rapid diagnosis. A previous study reported that the xTAG GPP for gastrointestinal patho-
gens increased laboratory testing costs but decreased total costs for hospitalization by reducing patient isolation 
 days3,17. The Verigene EP test might have similar effects; however, further studies are required.
While the Verigene EP test showed 19 discrepant results compared to the reference methods, the discrepant 
analysis proved that the Verigene EP test might have provided true results, at least in some samples with discrep-
ant results. If bacteria were detected by molecular method but not cultured, we should recognize both possibili-
ties; that the results of molecular methods may be false positives and that the sensitivity of cultures is lower than 
that of molecular  methods18–20. A previous study described that the culture method failed to detect Campylobacter 
in 30% of positive clinical samples compared to non-cultural methods, including molecular  assays21. Addition-
ally, if the xTAG GPP was not the best test in some cases, as described  previously11, the false-positive results of 
the Verigene EP test could result from the false-negative results of the xTAG GPP in the discrepant analysis.
Although each institution needs to consider how best to use the Verigene EP test effectively in daily prac-
tice, the test may be suitably used for community-acquired diarrhea requiring hospitalization to rapidly screen 
unmissable pathogens. Conversely, for hospital-acquired diarrhea, we might have to initially perform the Veri-
gene Clostridium difficile nucleic acid test, which is a separate test for a single pathogen and performed using 
the same Verigene  System12,22.
This study has some limitations. First, we could not adequately assess the ability of this test to detect Shigella 
species in clinical samples because the number of positive samples was limited. Instead, the Verigene EP test 
could successfully detect S. sonnei in characterized stool samples, and previous studies reported that the sensitiv-
ity and specificity of the Verigene EP test for the detection of Shigella species was 87.5–95.4% and 99.1–99.8%, 
 respectively3,4. Furthermore, because we did not collect patient information and did not test all samples submitted 
to our laboratories during the study period, we could not validate the pathogenicity of the detected pathogens 
and the incidence of infections. Reportedly, some Stx 1 and 2 subtypes are linked to mild diseases or are rarely 
involved in human  diseases23. Finally, for detecting bacteria and toxins, we could not assess the efficiency of the 
Verigene EP test compared to other molecular assays because another molecular method was used only for the 
discrepant analysis.
In conclusion, the Verigene EP test is useful for detecting crucial diarrheagenic pathogens, and may have 
applications in daily clinical practice. Further studies are needed to establish practical diagnostic strategies for 
the complementary use of molecular assays and traditional methods.
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